Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries

Affiliations

¹ CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, UK.
² Division of Rheumatology, University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
³ Department of Medicine, Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil.
⁴ Department of Rheumatology, APHP, Pitie Salpetriere Hospital, Pierre and Marie Curie University, Paris, France.
⁵ Department of Rheumatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
⁶ Genentech, South San Francisco, CA, USA.
⁷ F. Hoffmann-La Roche, Basel, Switzerland.

Published Erratum

Ernest Choy et al. Rheumatology (Oxford). 2018.

. 2018 Jun 1;57(6):1129.

doi: 10.1093/rheumatology/key116.

¹ CREATE Centre, Division of Infection and Immunity, Cardiff University, Cardiff, UK.
² Division of Rheumatology, University of Pavia and IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
³ Department of Medicine, Universidade Federal do Rio Grande do Sul Porto Alegre, Rio Grande do Sul, Brazil.
⁴ Department of Rheumatology, APHP, Pitie Salpetriere Hospital, Pierre and Marie Curie University, Paris, France.
⁵ Department of Rheumatology, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.
⁶ Genentech, South San Francisco, CA, USA.
⁷ F. Hoffmann-La Roche, Basel, Switzerland.

No abstract available

Erratum for

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.
Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A. Choy E, et al. Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Rheumatology (Oxford). 2018. PMID: 29244149 Free PMC article. Clinical Trial.